Serogroup A meningococcal epidemics have been a recurrent public health problem,
especially in resource-poor countries of Africa. Recently, the administration in mass …

The introduction and rollout of a meningococcal serogroup A conjugate vaccine,
MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal …

The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVacR, has
been a important public health success. Group A meningococcal meningitis has …

The introduction of a serogroup A meningococcal conjugate vaccine in the African
meningitis belt has been a remarkable success. Meningitis due to the serogroup A …

Endemic and epidemic meningococcal disease constitutes a major public-health problem in
African countries of the'meningitis belt'where incidence rates of the disease are many-fold …

For more than a century, epidemic meningococcal disease mainly caused by serogroup A
Neisseria meningitidis has been an important public health problem in sub-Saharan Africa …

In the last decade, meningococcal serogroup C conjugate vaccination programs have been
demonstrated to be hugely successful with a truly impressive public health impact. In sub …

Group A meningococcal disease has been an important public health problem in sub-
Saharan Africa for over a century. Outbreaks occur there annually, and large epidemics …

Epidemic meningococcal meningitis is a priority disease for prevention and control in Africa.
The current World Health Organization (WHO) approach to the control of meningitis …

Over the last 4 years, a remarkable public health success has unfolded in Africa. The field
introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), has …